| 陈晓丽,孔祥图,于慧,等.消癌解毒方联合化疗对弥漫大 B细胞淋巴瘤外周血 CD4+CD25+CD127low调节性 T细胞的影响[J].安徽医药,2023,27(1):164-169. |
| 消癌解毒方联合化疗对弥漫大 B细胞淋巴瘤外周血 CD4+CD25+CD127low调节性 T细胞的影响 |
| Effects of Xiaoai Jiedu prescription combined with chemotherapy regimen on peripheral blood CD4+CD25+CD127low regulatory T cells in diffuse large B-cell lymphoma |
| |
| DOI：10.3969/j.issn.1009-6469.2023.01.036 |
| 中文关键词: 淋巴瘤，大 B细胞，弥漫性 消癌解毒方 抗肿瘤联合化疗方案 T淋巴细胞，调节性 CD4阳性 T淋巴细胞 |
| 英文关键词: Lymphoma,large B-cell,diffuse Xiaoai Jiedu prescription Antineoplastic combined chemotherapy protocols T-lymphocytes,regulatory CD4-positive T-lymphocytes |
| 基金项目:国家中医药管理局第四批全国中医优秀人才研修项目(国中医药办人教函〔 2017〕24号)；江苏省中医药局面上项目( YB2017014)；江苏省卫生健康委科研项目( ZD2021040) |
|
| 摘要点击次数: 818 |
| 全文下载次数: 252 |
| 中文摘要: |
| 目的检测初诊弥漫大 B细胞淋巴瘤( DLBCL)采用 R-CDOP(利妥昔单抗联合环磷酰胺、脂质体多柔比星、长春新碱及泼尼松)方案联合或不联合消癌解毒方治疗前后外周血调节性 T细胞( Treg)百分比的变化，探讨 Treg对于 DLBCL发病及预后可能的影响以及消癌解毒方是否具有调控 Treg表达的作用。方法入组 2018年 1月至 2022年 1月南京中医药大学附属医院收治的初诊 DLBCL病人共 47例(治疗组 24例，对照组 23例)和健康对照 45例，治疗组采用消癌解毒方联合 R-CDOP方案，对照组单纯采用 R-CDOP方案治疗，两组均化疗 6个周期，采用流式细胞术检测两组病人治疗前后及健康对照的外周血 CD4+CD25+CD127low Treg百分比，观察两组病人的临床疗效以及治疗前后 CD4+CD25+CD127low Treg百分比的变化。结果治疗前，治疗组及对照组两组病人和健康对照的 CD4+ CD25+ CD127low Treg百分比中位数分别为 6.01%、5.73%、7.32%，两组病人外周血 Treg百分比均低于健康人( P<0.05)。治疗 6周期结束后，治疗组及对照组两组病人的 CD4+ CD25+ CD127low Treg百分比中位数分别为 7.33%和 5.85%，治疗组 Treg百分比较治疗前明显上升( P<0.05)对照组治疗前后 Treg百分比变化差异不明显(P>0.05)。治疗组和对照组相比，治疗组比对照组的 CD4+CD25+CD127low Treg百分，比明显上升( P<0.05)。两组病人临床疗效评估结果比较，治疗组和对照组的总缓解率( ORR)分别为 79.17%和 69.56%，两组 ORR差异无统计学意义( P>0.05)。结论消癌解毒方有可能通过上调 DLBCL病人失衡的 Treg百分比发挥调控肿瘤免疫环境的作用。 |
| 英文摘要: |
| Objective To study the changes of regulatory T cell (Treg) percentage in peripheral blood before and after treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL) with R-CDOP (rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, and prednison) chemotherapy regimen combined with or without Xiaoai Jiedu prescription, and to explore the possible impact of Treg on pathogenesis and prognosis of DLBCL, and whether Xiaoai Jiedu prescription plays a role in regulating Treg expression.Methods A total of 47 newly diagnosed DLBCL patients (24 in treatment group and 23 in control group) and 45 healthy volunteers from The Affiliated Hospital ofNanjing University of Chinese Medicine from January 2018 to January 2022 were enrolled. Patients in treatment and control group weregiven Xiaoai Jiedu prescription combined with 6 cycles of R-CDOP chemotherapy regimen and 6 cycles of R-CDOP chemotherapy regimen alone, respectively. The CD4+ CD25+ CD127low Treg percentage in patients′ peripheral blood of these two groups before and after treatment and that of the healthy controls as well were detected by flow cytometry. The clinical outcome of these two groups of patients andchanges in the percentage of CD4+CD25+CD127lowTreg before and after treatment were observed.Results Before treatment, the median percentages of CD4+ CD25+ CD127low Treg in treatment group, control group and healthy control group were 6.01%, 5.73% and 7.32%, respectively, and the percentage of these two groups (treatment group and control group) was lower than that of the healthy volunteers (P< 0.05). After 6 cycles of treatment, the median percentages of CD4+ CD25+ CD127low Treg in the treatment group and the control group were7.33% and 5.85%, respectively, and the percentage of Treg in the treatment group was significantly higher than that before treatment (P<0.05). The percentages of Treg in the control group showed no significant difference before and after treatment (P>0.05). Compared with the control group, the percentage of CD4+CD25+CD127lowTreg in the treatment group was significantly higher than that in the control group (P<0.05). Comparison of clinical efficacy evaluation results between the two groups showed that the overall response rates (ORR) ofthe treatment group and the control group were 79.17% and 69.56%, respectively, and the ORR of the treatment group was higher thanthat of the control group, but the difference was not statistically significant (P > 0.05).Conclusion Xiaoai Jiedu prescription may play arole in regulating tumor immune environment by upregulating the percentage of imbalanced Treg in DLBCL patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
